Get The Latest
Molecular targets and targeted therapies for malignant mesothelioma - Tue, 01 Jul 2008
Source: Current Medicinal Chemistry
Some of the most important work in contemporary mesothelioma research involves the attempt to create targeted therapeutic agents which work directly on the cellular aberrations that are ultimately responsible for the development of ple...
Mesothelioma Patient Profile: Charlene Kaforey - Mon, 30 Jun 2008
We have traditionally used the “Recent News” section of this website to report on the latest findings in mesothelioma and asbestos research. Most of the stories we’ve covered have been summaries of the latest articles from scientific journals, so the content has been fairly technical. We will continue to report on all of the latest researc...
MR Imaging of Benign and Malignant Pleural Disease - Thu, 26 Jun 2008
Source: Magnetic Resonance Imaging Clinics of North America
Radiological imaging technologies are among the most important tools available for the diagnosis of mesothelioma and other forms of cancer, as they can render the status and structure of the interior landscape of a patient’s body without the need for invasive, exploratory ...
59th mesothelioma case reported among miners - Fri, 13 Jun 2008
Source: Duluth News Tribune
The Duluth News Tribune is reporting that a 59th case of mesothelioma has been identified in the population of Iron Range workers whose extremely high incidence rate of the disease has sparked national attention on Minnesota’s Iron Range. The case was identified when data from the Minnesota Healt...
Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies - Thu, 12 Jun 2008
Source: Current Medicinal Chemistry
Mesothelioma is a complex cancer that remains difficult to treat effectively. There is no cure for the disease and the standard therapies, even in the best of cases, can only extend life. Because of this, investigations into the basic physical processes responsible for its development m...
Merck's International Study of Vorinostat (ZOLINZA) in Patients with Mesothelioma Proceeds to Phase III Development - Tue, 10 Jun 2008
Source: Mesothelioma Applied Research Foundation
Merck has recently announced that its clinical trial of Vorinostat as second-line therapy for pleural mesothelioma patients who’ve failed the standard New York Times
The New York Times Health Section has recently published an article on the debate regarding what the appropriate treatment response should be for the discovery of micrometastatic lymph node involvement in a cancer patient. Doctors have long used lymph node status as an important indicator of patient PharmaLive.com
The European Commission, which is the executive branch of the European Union, has granted “Orphan Drug” status to Arenegyr, an anti-cancer drug currently under investigation for the treatment of mesothelioma, as well as a number of other cancers. Arenegyr is an experimental vascu...
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma - Fri, 30 May 2008
Source: Lung Cancer
Mesothelioma remains one of the most difficult cancers to treat effectively. Even as improvements to the standard therapies have led to small increases in overall survival time for some patients, the disease remains without a cure and most patients diagnosed with Japanese Journal of Clinical Oncology
Even though mesothelioma remains without cure, improvements in the traditional mesothelioma treatments have led to an increase in median survival times for many types of patients. The success of the
